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ABSTRACT
Background: Currently mainly BRAF mutant circulating tumor DNA (ctDNA) is 
utilized to monitor patients with melanoma. TERT promoter mutations are common in 
various cancers and found in up to 70% of melanomas, including half of BRAF wild-
type cases. Therefore, a sensitive method for detection of TERT promoter mutations 
would increase the number of patients that could be monitored through ctDNA 
analysis.
Methods: A droplet digital PCR (ddPCR) assay was designed for the concurrent 
detection of chr5:1,295,228 C>T and chr5:1,295,250 C>T TERT promoter mutations. 
The assay was validated using 39 melanoma cell lines and 22 matched plasma and 
tumor samples. In addition, plasma samples from 56 metastatic melanoma patients 
and 56 healthy controls were tested for TERT promoter mutations.
Results: The established ddPCR assay detected TERT promoter mutations with 
a lower limit of detection (LOD) of 0.17%. Total concordance was demonstrated 
between ddPCR and Sanger sequencing in all cell lines except one, which carried 
a second mutation within the probe binding-site. Concordance between matched 
plasma and tumor tissue was 68% (15/22), with a sensitivity of 53% (95% CI, 27%-
79%) and a specificity of 100% (95% CI, 59%-100%). A significantly longer PFS 
(p=0.028) was evident in ctDNA negative patients. Importantly, our TERT promoter 
mutations ddPCR assay allowed detection of ctDNA in 11 BRAF wild-type cases.
Conclusions: The TERT promoter mutation ddPCR assay offers a sensitive test for 
molecular analysis of melanoma tumors and ctDNA, with the potential to be applied 
to other cancers.
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 45), pp: 78890-78900
                                                             Research Paper
Oncotarget78891www.impactjournals.com/oncotarget
INTRODUCTION
Telomerase reverse transcriptase (TERT) encodes 
the catalytic subunit of telomerase, a ribonucleoprotein 
responsible for maintaining telomere length of chromosomes 
which play an integral role in cell immortality. Using 
linkage analysis and high-throughput sequencing, Horn 
et al. [1] reported somatic mutations in 74% of metastatic 
melanoma human cell lines, 85% of metastatic melanoma 
tumor tissues and 33% of primary melanomas. These 
mutations are the result of a cytidine to thymidine transition 
in the promoter of the TERT gene, at chromosome 5, 
1,295,228 C>T and 1,295,250 C>T, hereafter termed C228T 
and C250T. These mutations create a putative consensus 
ETS (E26 transformation-specific) /ternary complex 
factor binding motif (GGAA/T), which is associated with 
an increase in TERT expression [1, 2]. The presence of 
these mutations in cutaneous melanoma is associated with 
fast growing melanomas [3] and poor prognosis [4]. The 
co-existence of TERT promoter mutations with BRAF or 
NRAS mutations (in 55% of cases) is associated with poor 
disease-free and melanoma-specific survival [5]. TERT 
promoter mutations occur frequently in a number of other 
cancers: 80–90% of glioblastoma multiforme, 60% of 
hepatocellular carcinoma, 60% of bladder cancer, 70% 
of basal cell carcinoma, 50% of cutaneous squamous cell 
carcinoma and up to 30% of thyroid cancers [6-11] and are 
associated with aggressive disease in thyroid carcinoma 
[12], glioblastoma [13], neuroblastoma [14] and renal cell 
carcinoma [15]. Therefore, it is of significant clinical benefit 
to develop a non-invasive and sensitive test that determines 
the TERT promoter mutation status in cancer patients.
Molecular profiling of tumors to aid cancer 
prognosis and to identify actionable therapeutic targets has 
become routine practice in clinical oncology. Whilst tumor 
tissue samples are typically used for mutation analysis, 
access to the tumor for biopsy, and the quality and quantity 
of the sample may hinder detection, particularly when 
methods with limited sensitivity are employed. Commonly 
used methods include Sanger sequencing, melting 
curve analysis and pyrosequencing which have limits 
of sensitivity of 15%-20%, 10% and 5% respectively 
[16]. More recently, tumor related aberrations have been 
determined in plasma cell free DNA (cfDNA) [17-22]. 
This is referred to as “liquid biopsy”, a relatively non-
invasive test that can be performed regularly and provides 
information from the sum of all tumors at any one time 
point. It is, therefore, a valuable biomarker for monitoring 
disease progression and response to therapy [19, 23].
Whilst a variety of methods have been used to detect 
mutations from circulating tumor DNA (ctDNA), Hindson 
et al., have shown droplet digital PCR (ddPCR) to be a 
highly sensitive platform, enabling absolute quantitation 
of mutant BRAF down to 0.001% allelic fraction [24]. 
Various studies have since shown the utility of testing 
mutant BRAF in plasma of melanoma patients using 
ddPCR [18, 23, 25-27]. In particular, our laboratory has 
demonstrated that ctDNA analysis allows tracking of 
patient response to therapy and resistance acquisition 
[23]. Given the high prevalence of the TERT promoter 
mutations C228T and C250T in cutaneous melanoma 
[5, 28], their addition to existing tests for detection of 
mutant BRAF and NRAS will allow monitoring of most 
melanoma patients using ddPCR. Furthermore, it has 
been shown that concurrence of mutations in the TERT 
promoter with BRAF or NRAS mutations predispose 
patients to fast growing and aggressive disease, thus 
detection of multiple mutations including mutant TERT 
could serve as a prognostic marker.
We report here on the development of a ddPCR 
probe based assay to simultaneously detect the TERT 
promoter mutations C250T and C228T. One probe binds 
the wild-type sequence overlapping position C228, while 
a second probe binds the mutant sequence resulting from 
C228T or C250T mutations, as both mutations reconstitute 
the putative ETS binding site (Figure 1). First, we tested 
the concordance of this assay for the detection of TERT 
promoter mutations in 39 melanoma cell lines relative 
to Sanger sequencing, and in 22 plasma samples relative 
to patient matched tumor tissue. We also determined the 
sensitivity and specificity of this assay for the detection of 
TERT promoter mutations using plasma derived cfDNA 
from 56 melanoma patients and 56 healthy controls.
RESULTS
The designed primer sets were tested for amplification 
of the genomic region of interest by end-point PCR. 
Amplification conditions were optimized by testing a range 
of annealing temperatures (55-61ºC). As shown in Figure 
2A, the primers failed to amplify the required fragment in 
the absence of Q-solution (Qiagen). Optimal amplification 
was achieved in the presence of Q-solution between 
61-64ºC (Figure 2B). The PCR fragment obtained was 
subjected to Sanger sequencing to confirm its specificity.
Next, droplet digital PCRs were performed at a 
gradient of annealing temperatures from 52°C to 65°C 
for the detection of the C228T mutation in gDNA from 
1205Lu cells (Figure 2C and 2D) and the C250T mutation 
in gDNA from UACC62 cells (Figure 2E and 2F). Optimal 
droplet segregation was observed at 57°C. Hereafter 
all ddPCR assays were performed with an annealing/
extension temperature of 57°C.
To evaluate the quantitative linearity and the limit 
of detection (LOD) of the ddPCR assay, serial dilutions of 
mutant gDNA from cell lines 1205Lu (C228T mutant) and 
UACC62 (C250T mutant) were mixed in a background 
of wild-type human genomic DNA to achieve a final 
concentration of gDNA of 20 ng/μL (Figure 3), with each 
dilution tested in 8 replicates. At 0% mutant DNA, we 
identified that a maximum of 2 false positive droplets were 
observed in some of the 8 replicates, with an average of 
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0.068 ± 0.049%. Therefore, the lower LOD was defined 
at 0.17%, the percentage false positives detectable at two 
standard deviations over mean background [29].
To validate the assay, we tested 39 cell lines with 
known TERT promoter mutant or wild-type status (Table 
1). We confirmed detection of the C228T and/or the 
C250T TERT promoter mutation in only those cell lines 
identified as positive for these two mutations, while those 
previously identified as wild-type showed no positivity for 
TERT DNA mutations by ddPCR. Cell lines that harbored 
an alternative TERT mutation other than C228T or C250T 
showed as wild-type in our assay. In addition, the C250T 
mutation was not detected in cell line C021, due to the 
presence of a C253T single nucleotide polymorphism 
in the probe binding site (Supplementary Figure 1). 
Simultaneous C250T and C253T mutations have been 
reported in 2% of melanoma cells lines [1].
Tumor tissue samples from 22 stage IV (AJCC) 
metastatic melanoma patients were tested for C228T and 
C250T TERT promoter mutations by ddPCR using the 
TERT assay (Table 2). As reported in the literature [4, 28, 
30], most tumor tissues tested harbored at least one of these 
mutations (68%, n=15); 11 harbored the C228T mutation 
and 4 harbored the C250T mutation. No tissue samples 
were found to contain both TERT promoter mutations.
Plasma derived cfDNA from these 22 patients 
were also tested for TERT promoter mutations. These 
plasma samples were collected from patients with active 
metastatic disease prior to any systemic therapeutic 
intervention. Overall, the concordance rate between tumor 
tissue and plasma testing was 68% (15/22). No patient 
was positive for a TERT promoter mutation in plasma 
and negative in its corresponding tumor tissue (100% 
specificity). Of 15 plasmas from patients with confirmed 
TERT promoter positive tumors, 8 were identified as 
positive for the same mutation, whereas 7 cases were 
positive in the tissue but negative in the plasma sample 
(Table 2). Thus, the sensitivity of our TERT C228T/C250T 
mutation detection in plasma was estimated as 53% (95% 
CI 27%-79%). In a cox regression analysis, patients with 
detectable ctDNA at baseline (n=8) had a significantly 
shorter progression free survival (PFS) compared to 
patients that had no detectable ctDNA (n=7) (p=0.028, 
Hazard ratio: 4.48 (CI, 1.18-17.06) (Figure 4A).
To further demonstrate the detection rate of TERT 
ctDNA in metastatic melanoma we tested 56 plasma 
samples from randomly selected stage IV (AJCC) 
melanoma patients (mean age 65 years, ranging from 
35 to 85 years) with known BRAF but unknown TERT 
mutational status and compared this to 56 plasma samples 
from healthy individuals (mean age 51 years, ranging 
from 24 to 81 years). The TERT ddPCR assay detected a 
statistically significant difference in the copies of mutant 
TERT ctDNA in plasma from metastatic melanoma 
patients relative to those from healthy controls (p=0.006, 
Figure 4). We found TERT mutant DNA in 11 of 38 BRAF 
wild-type and in 4 of the 18 BRAF V600E/K patients. 
The number of TERT promoter copies per mL of plasma 
detected in the melanoma patient cohort varied from 11.2 
to 176 copies per mL (Figure 4). No TERT promoter 
mutant DNA was detected in any of the 56 healthy control 
plasmas. Based on these results the assay specificity was 
estimated as 100% (95% CI 94%-100%).
DISCUSSION
Here we describe and validate a method to detect 
the two most common TERT promoter mutations found 
in melanoma tumors using ddPCR. TERT promoter 
mutations occur in melanoma as frequently as [4], or more 
frequently [5] than BRAF mutations, and yet mainly BRAF 
mutant specific cfDNA is being used to monitor melanoma 
patients for response to therapy and disease progression 
[26]. The inclusion of TERT promoter mutations within 
ctDNA for monitoring would increase the number of 
patients for whom ctDNA could be used to determine 
Figure 1: Location of ddPCR assay probes relative to ETS1 binding motifs generated by the C228T and C250T TERT 
promoter mutations. Probes for the identification of wild-type and mutant sequences are indicated. Both mutant sites are detected by 
the same probe.
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disease status, particularly amongst BRAF and NRAS wild-
type melanoma patients. This will enable large studies 
on the clinical utility of ctDNA monitoring to provide 
evidence of the efficacy of this marker for determining 
disease progression, to inform cessation of ineffective 
therapies [23, 27] and to guide alternative therapy.
Our assay allowed for detection of mutant TERT 
in biologically relevant samples, such as FFPE tumor 
DNA and plasma of metastatic melanoma patients at high 
specificity. Using cell line derived DNA, we optimized 
the assay to detect as little as 0.17% mutant TERT DNA 
in dilutions of wild-type DNA. This is significantly 
lower than limits of detection reported for other mutation 
detection platforms such as allele specific PCR at 1% [31] 
and pyrosequencing at 5%, melting curve analysis at 10% 
and Sanger sequencing at 20% [16]. While we and others 
have shown ddPCR to detect BRAF mutant fraction as 
low as 0.001% [24, 32], we were unable to achieve this 
sensitivity with the TERT assay developed here, possibly 
due to the highly GC rich area of the promoter region 
of this gene, resulting in background signal and limited 
segregation of positive and negative droplets. In fact, 
during the development of this assay, multiple primers, 
probes and amplification conditions were tested without 
success. The conditions detailed here, including the 
addition of LNA at the specific nucleotides and the use of 
Q-solution in the amplification mix, were indispensable 
for successful amplification.
We validated the assay in terms of accuracy 
and reliability by showing 97.4% concordance with 
the genotype of 39 melanoma cell lines. Of the cell 
lines analyzed that harbored either a C228T or C250T 
Figure 2: Optimization of ddPCR for detection of TERT promoter mutations. PCR fragments from cell line 1205Lu amplified 
at varying temperatures without (A) and with (B) “Q solution”. gDNA of cell lines 1205Lu-C228T (C and D) and UACC62-C250T (E and 
F) were used as template for the TERT ddPCR at varying annealing temperatures. FAM signal from mutant probe binding to C228T (C) or 
C250T (E). HEX signal from binding of wild-type probe (D and F).
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mutation, 14 were heterozygous and 9 homozygous. 
A major limitation of our assay is that it cannot detect 
other TERT promoter mutations and it can be affected by 
SNPs within the probe binding sites. This was apparent 
by the results obtained from 9 cell lines with known 
TERT promoter dinucleotide mutations C227T/C228T 
and C241T/C242T, which have been reported to exist 
in 5.2% and 10.4% of primary melanomas respectively 
[1]. Similarly, a negative result was reported for cell line 
CO12 which harbors a C253T SNP on the probe binding 
site. Further development of ddPCR assays to detect these 
other TERT promoter mutations [5] would ensure that 
a maximum number of patients could be monitored. In 
addition and given that SNPs in this region can also affect 
patient prognosis [5], germline sequence analysis should 
be performed complementary to the analysis of TERT 
promoter somatic mutations.
It is notable that all patients with TERT promoter 
mutations in plasma had corresponding mutations in 
matched tumor tissue and as such no false positive plasma 
samples were detected. High concordance between 
mutational profiles in plasma ctDNA and matched tumor 
tissue have been reported in several studies from patients 
with melanoma [18, 25, 26], breast cancer [20, 33, 34], 
Figure 3: Detection of TERT promoter mutations in the presence of homologous wild-type DNA. Serial dilutions of DNA 
from mutant cell lines 1205Lu – C228T (A-D) and UACC62 – C250T (E-H) were prepared in a constant background of wild-type human 
genomic DNA. 2D plots of ddPCR read out at 10% of mutant DNA (A and E). 1D plots indicating mutant (B and F) and wild-type (C and G) 
DNA detection. Analytical sensitivity (LOD) of the assay (D and H). Obtained frequency abundances and standard deviations were plotted 
versus expected mutant frequencies based on input. The LOD, defined as 2 SD over the mean frequency abundance obtained at 0% when 
only wild-type DNA was used as input, was indicated as dashed lines in both graphs.
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Table 1: Validation of C228T and C250T TERT promoter mutation detection in melanoma cell lines
Cell line Sanger sequencing ddPCR
C024 wt wt
C055 wt wt
C092 wt wt
C096 wt wt
HGA wt wt
C022 C228T C228T
C037 C228T C228T
C058 C228T C228T
D41 C228T C228T
MM409 C228T C228T
D22 C228T C228T
MM473 C228T C228T
A06 C228Ta C228Ta
C076 C228Ta C228Ta
MM455 C228Ta C228Ta
1205Lu C228Ta C228Ta
A15 C250T C250T
A14 C250T C250T
C002 C250T C250T
MM537 C250T C250T
SKMEL13 C250T C250T
MM386 C250T C250T
D01 C250T C250T
MM229 C250Ta C250Ta
MM253 C250Ta C250Ta
MM266 C250Ta C250Ta
C001 C250Ta C250Ta
C045 C250Ta C250Ta
D40 C250Ta C250Ta
UACC62 C250Ta C250Ta
MM396 C227T/C228T wt
A07 C227T/C228T wt
C054 C227T/C228T wt
C062 C227T/C228T wt
C057 C241T/C242T wt
C108 C241T/C242T wt
D28 C241T/C242T wt
SKMEL5 C241T/C242T wt
C021 C250Tb wt
aHomozygous
bC021 carried an additional C253T polymorphism.
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non-small cell lung cancer [35, 36] and colorectal cancer 
[17, 20, 37]. In our study, 7 patients with TERT promoter 
positive tumors had no detectable TERT promoter mutations 
in matched plasma samples. This is similar to the findings 
by Lee et al, who detected ctDNA in 53% of patients prior to 
treatment initiation [38]. The lack of detectable ctDNA in a 
subset of patients may be explained by the pathophysiology 
of the tumor or its metastasis, as ctDNA concentration has 
been correlated with tumor size [38-40], metastatic spread 
or disease burden [25, 38, 41], tumor vascularization [42] 
and site of metastasis [20]. A retrospective analysis of PFS 
in this group of patients revealed a significant difference 
between patients with negative and positive ctDNA 
results. This further supports previous findings that low 
or undetectable level of ctDNA is a predictor of long term 
treatment benefit [18, 23, 25, 26, 38].
Previous studies have reported detection rates 
for BRAF V600E mutations in plasma of metastatic 
patients at 76 to 84.3% [25, 26] and for BRAF V600K 
at 81 to 89% [18, 26]. In other cancers, Bettegowda et 
al. [20] identified mutant ctDNA in 75% of patients with 
a variety of cancers including ovarian, breast, bladder, 
gastroesophageal and colorectal cancers. Considering our 
detection rates of TERT promoter mutations in ctDNA 
are lower (53%) than these reports, it would be necessary 
for this investigation to be conducted in a larger cohort 
controlling for tumor burden, metastatic sites and mutation 
variety. Nevertheless, our TERT promoter mutation assay 
allowed ctDNA detection in 11 of 38 BRAF wild-type 
tumors. Thus, our assay may facilitate ctDNA monitoring 
on BRAF wild-type cases, most of which will receive 
immunotherapy as a first line of treatment.
Nagore and colleagues [5] have shown that melanoma 
patients harboring these specific TERT promoter mutations, 
in combination with BRAF/NRAS mutations within their 
tumor tissue, have a significantly shorter disease free 
survival than patients without this combination. In fact, 
Li et al., have shown that TERT promoter mutations are key 
downstream targets of the RAS-ERK pathway for malignant 
progression of BRAF mutant melanomas [43]. Furthermore, 
Akincilar et al. [44] have shown that TERT transcription is 
driven by mediation of long-range chromatin interaction and 
enrichment of active histone marks through the recruitment 
of GABPA to mutant TERT promoters, specifically C228T 
and C250T. These authors have consequently suggested that 
inhibitors could be designed to hinder TERT transcription in 
cancer cells with these mutations. As such, routine genetic 
testing of melanoma patients for TERT promoter mutations 
in addition to mutant BRAF and NRAS would be clinically 
beneficial.
Table 2: Detection of TERT promoter mutations in ctDNA and paired tumor tissue
Tumor Tissue
Plasma ctDNA + − Total
+ 8 0 8
− 7 7 14
Total 15 7 22
Figure 4: Detection of TERT promoter mutations in plasma. (A) Kaplan-Meier plots of PFS probabilities of patients with 
detectable (n=8) and undetectable (n=7) ctDNA levels at baseline. Cox regression p-value, Hazard ratio (HR) and confidence interval 
(CI) are indicated. (B) Copies of mutant DNA per mL of plasma were significantly higher in metastatic melanoma patients (MM) (N=56) 
compared to healthy controls (Ctrls) (N=56). P=0.006, Mann-Whitney U-test.
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TERT promoter mutations have been identified 
in numerous other cancers such as thyroid, bladder, 
hepatocellular cancer and malignant glioblastoma [6-8]. 
Consequently, the assay described here may allow ctDNA 
monitoring in multiple other malignancies. However, the 
assay would require validation for each of these cancers.
In conclusion, we report on the development of 
a ddPCR assay for the detection of two common TERT 
promoter mutations in cell lines, tumor tissue and 
ctDNA. Our results suggest that the TERT ddPCR assay 
could prove useful as a companion diagnostic to predict 
treatment benefit and to monitor response in melanoma 
patients and could be extended to other malignancies.
MATERIALS AND METHODS
Ethics
This study was approved by the Human Ethics 
Committees at Edith Cowan University (No. 11543) and 
Sir Charles Gairdner Hospital (No.2013-246).
Genomic DNA extraction
Genomic DNA (gDNA) with known TERT promoter 
mutations was obtained from melanoma cell lines 1205Lu 
(Wistar Institute) and UACC62 (National Cancer Institute) 
to be used as positive controls. In addition, gDNA was 
extracted from 39 melanoma cell lines from the QIMR 
Berghofer Medical Research Institute [45]. Wild-type 
gDNA was obtained from the white blood cell pellets 
collected from 4 mL whole blood from one healthy 
control. DNA was isolated using the QIAamp DNA 
Mini Kit (Qiagen, Australia) as per the manufacturer’s 
instructions. gDNA was eluted in AE buffer (Qiagen) and 
stored at 4°C until further processing.
Plasma sample preparation
Blood samples were collected from American 
Joint Committee on Cancer (AJCC) stage IV melanoma 
patients, prior to initiation of any systemic therapy, into 
EDTA vacutainer tubes and stored at 4°C. Plasma was 
separated within 24 hours by centrifugation at 1600 g for 
10 minutes, followed by a second centrifugation at 2000 g 
for 10 minutes, then stored at -80°C until extraction.
DNA extraction from plasma
cfDNA was isolated from 5 mL of plasma from 
healthy donors and AJCC stage IV metastatic melanoma 
patients using the QIAamp Circulating Nucleic Acid Kit 
(Qiagen) as per the manufacturer’s instructions. cfDNA 
was eluted in 40 μl AVE buffer (Qiagen) and stored at 
-80°C until ctDNA quantification.
DNA extraction from FFPE tissue
Following review and macrodissection by an 
experienced pathologist, genomic DNA (gDNA) was 
extracted from 10 x 5μm unstained sections of FFPE 
tissue using the QIAamp DNA mini kit (Qiagen) as per 
the manufacturer’s instructions. Only FFPE tissues stored 
at room temperature, for less than 7 years were used. The 
DNA concentration and purity was determined using 
the NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE) and Qubit 2.0 Fluorometer 
(Life Technologies, USA) instruments.
PCR
The following primers were used to amplify a 
163bp product incorporating both hotspot mutations 
(C228T and C250T) in the TERT promoter region: 5’- 
AGCGCTGCCTGAAACTCG -3’ (forward) and 5’- 
CCTGCCCCTTCACCTTCCAG -3’ (reverse). Primers 
were synthesized by GeneWorks (Thebarton, SA, 
Australia). For optimization of the PCR amplification of 
TERT promoter mutations, we first performed end point 
PCRs containing, 1 x ddPCR supermix (Bio-Rad), 900 
nM of each primer and 50 ng of template gDNA, with 
and without 1 x Q solution (Qiagen). Amplifications were 
performed using the following cycling conditions: 1 cycle 
of 95°C for 15 minutes, 40 cycles of 95°C for 30 seconds 
and a range of temperatures from 55°C to 65°C for 30 
seconds, followed by 68°C for 30 seconds and 1 cycle 
of 68°C for 10 minutes. PCR products of 163bp were 
detected by gel electrophoresis on a 1% agarose gel in 
Tris-acetate-EDTA (TAE) buffer containing SYBR® Safe 
DNA Gel Stain (Life Technologies).
Droplet digital PCR
A probe was designed to detect both C228T and 
C250T mutation as both mutations result in the same 
sequencing string (Figure 1). Due to the short size of 
the probe, Locked Nucleic Acid (LNA) bases were 
introduced on the bases indicated with a “+” (TERT 
Mut:/56-FAM/CCC+C+T+T+CCGG/3IABkFQ/). 
A second probe was designed to recognize the C228 
loci, also containing LNA bases, (TERT WT, /5HEX/
CCCC+C+T+CCGG/3IABkFQ/). Probes were custom 
synthesized by Integrated DNA Technologies (IDT). 
Amplifications were performed in a 20 μL reaction 
containing 1 x ddPCR Supermix for Probes (No dUTP, 
Bio-Rad), 1x Q solution (Qiagen), 250 nM of each probe 
and 900 nM of each primer plus template.
Droplets were generated using the Automatic 
Droplet generator QX200 AutoDG (Bio-Rad). 
Amplifications were performed using the following 
cycling conditions: 1 cycle of 95°C (2.5C/s ramp) for 
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10 minutes, 40 cycles of 94°C (2.5C/s ramp) for 30 
seconds and 57°C for 1 minute, followed by 1 cycle of 
98°C (2.5C/s ramp) for 10 minutes. Annealing/extension 
temperature was optimized using temperature gradients 
from 52°C to 65°C. The sample was held at 4°C until 
further processing. Droplets were analyzed through a 
QX200 droplet reader (Bio-Rad). QuantaSoft analysis 
software (Bio-Rad) was used to acquire and analyze data.
To evaluate the LOD of our TERT ddPCR assay, 
gDNA from cell lines 1205Lu (C228T) or UACC62 
(C250T) were serially diluted into normal human DNA 
obtained from white blood cells of healthy controls to 
achieve from 100% to 0% mutant alleles. Each dilution 
was tested in a series of eight repetitions all completed in 
one run.
Cell lines with known C228T and C250T TERT 
promoter mutations, as well as cell lines wild-type for both 
mutations (as determined by Sanger sequencing) were 
used to validate the assay. The reaction mix was prepared 
as above using 50 ng of gDNA as template.
For plasma ctDNA analysis, 5 μL of cfDNA 
(maximum template volume possible) was added per 
reaction irrespective of the cfDNA concentration. Each 
run included a non-template control, gDNA from a healthy 
control and gDNA from the cell lines containing the TERT 
mutations: 1205Lu (C228T) and UACC62 (C250T). 
Only samples with more than two positive droplets were 
considered positive. The number of mutated DNA copies 
per 20 μl reaction was extrapolated to calculate copies per 
mL using the following equation:
Copies/mL of plasma = C*EV/TV/PV.
PV = Volume of plasma used for cfDNA extraction (ml)
EV = Volume in which cfDNA was eluted (μl)
TV = Volume of cfDNA added to the PCR reaction (μl)
C = copies/20μl (data derived from QuantaSoft).
Statistical analysis
Sensitivity and specificity of the assay was calculated 
using a contingency table analyzed using a Fisher’s 
exact test. Comparison between ctDNA concentrations 
in patient and control samples were performed using the 
non-parametric Mann-Whitney U-test. A Cox proportional 
hazards regression analysis was performed to examine 
association of ctDNA detection with PFS. Statistical 
analyses were performed using Statistical Package for 
Social Sciences for Window version 22 (SPSS, Chicago, 
IL) and plotted using GraphPad Prism version 5.
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